Speaking at The Landscape of Cancer Research: Advances in Immuno-oncology in June 2024, Dr. Saba Ghassemi, Assistant Professor at the University of Pennsylvania Perelman School of Medicine presented her talk on breakthroughs in CAR-T cell technologies.
Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematologic malignancies, offering durable clinical responses. Despite their success, significant barriers limit their broader application, particularly against solid tumors. Traditional CAR T cell manufacturing involves a 9-14 day process of T cell activation, transduction, and expansion, which induces differentiation and reduces their anti-tumor efficacy. Moreover, solid tumor microenvironments create metabolic challenges that impair CAR T cell function. In this talk, we will provide an overview of several advances in CAR T cell therapies. We will discuss our novel approach to CAR T cell production, which eliminates the activation step to generate potent, non-activated CAR T cells within 24 hours.
15 окт 2024
